<- Go Home

Cipher Pharmaceuticals Inc.

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.

Market Cap

CAD 296.0M

Volume

29.2K

Cash and Equivalents

CAD 48.0M

EBITDA

CAD 12.1M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

CAD 18.0M

Profit Margin

81.08%

52 Week High

CAD 14.50

52 Week Low

CAD 3.02

Dividend

N/A

Price / Book Value

3.14

Price / Earnings

12.76

Price / Tangible Book Value

3.88

Enterprise Value

CAD 248.3M

Enterprise Value / EBITDA

20.42

Operating Income

CAD 11.0M

Return on Equity

28.43%

Return on Assets

7.90

Cash and Short Term Investments

CAD 48.0M

Debt

CAD 296.0K

Equity

CAD 88.8M

Revenue

CAD 22.2M

Unlevered FCF

CAD 5.5M

Sector

Pharmaceuticals

Category

N/A

Company Stock Pitches